

Kara Laing

From: Joy McCarthy
Sent: Tuesday, September 04, 2007 12:34 PM
To: Dolores Rice; Muhammad Zulfiqar; Kara Laing; Adnan Zaidi
Cc: Michael LeBlanc; Scott Edwards; Rick Abbott; Cynthia Higdon
Subject: breast chemo guidelines Sept 25

Hi,

Dolores has secured the room and we have most of the \$\$ so far. Now we just need to organise it. It will be from 230-630 and an hour for each topic - 4 topics. I will do Metastatic and Kara will do targetted therapies including Herceptin.

Zul and Adnan - could you guys do adjuvant ? perhaps divide by high risk (node positive and high risk node negative) and low/mod risk rather than pre-post men. We need to include growth factor support in all sections too. Best to do a treatment algorithm for each, I would think rather than spit out every trial known to man- maybe just go thru existing CCO/BC/ASCO guidelines and regurg an algorithm - alot less work.

I would like 30-40minutes for the talks and then 20-30 for discussion - the more discussion the better! Its alot to do so likely a working supper. We will pick entrees and I will pick the dessert and appetizer if thats ok - less hassell.

230-235 - welcome and outline

235-305pm - Metastatic Breast cancer - Joy (I am gonna do this case based and do an algorithm) - one case for HER2pos and one for HER neg. Both will be ER/PR neg for simplicity.

304-330pm - Discussion/Guideline for MBC

330-405 - Adjuvant high risk - Zul

405-430 - Discussion/Guideline for high risk

430-505 - Adjuvant low risk - Adnan

505-530 - Discussion/Guideline for low risk

530-600 - Targetted therapies including Herceptin - Kara

600 -625 - Discussion/Guideline for Targetted Therapies

625-630 - Wrap-Up

Joy

Joy McCarthy, M.D., FRCP(C)

Medical Oncologist

Director of Clinical Trials

Cancer Care Program - Eastern Health

300 Prince Philip Drive

St. John's, NL, A1B 3V6

Ph: (709) 777-7802 (w) or 777-7557 (trials)